this is not a problematic company, its the gahmen yg forced them to hsndle covid vaccine till over supply..when kovid gone..stuck with oversupply dose.. ask Kj ler. now, gahmen hv silently help to fix the problem. Nx Qr will be more prolific..high probability Revenue over 1b. Current price consider low already..good to enter. Down side minimum..upper side. 50 cents 👍
Look at other pharma players, their shares are all above RM2. This is the reason I said Pharmaniaga is underrated and it should be priced about RM4 if they are managing it well like others.
current management good already, managed to submit their restructuring plan early this year, you compare with other PN17 company, take yearssss to submit even the first plan. % months olready, and Bursa should give the approval anytime soon. I would expect this month.. BTW, Next QR should touch 1 billion revenue. Imagine how many people in Indonesia?? They just open news branch in Feb 2024.. next QR will be full 3 months (mac - June) sales.
" In the Indonesia segment, the revenue growth was due to the surge in demand for products of existing principals and additional sales generated from the opening of two new branches in February 2024."
it will keep moving up steadily until the next QR released, if the report is good it will goes up further above RM1, and how high it could goes higher depends on the consistency of their financial performance as well as dividend given.
for those who still have bullets may consider to get a train ticket asap as the gap of the stock price as of now to it supposed to be is big. big potential stock for mid term good profit investment.
It will be keep going up for sure as the company is in good shape now and keep improving from varies aspects. Bear in mind pharma is essential and is must + Pharmaniaga is the sole appointed supplier of nation.
And the catalyst that is likely to change the fortunes of the company — a proposed renounceable rights issue with warrants as a sweetener to shareholders that is slated to raise up to RM354.6 million; and, more importantly, a proposed private placement to a third-party investor or investors that could raise gross proceeds of up to RM300 million — could happen soon. Both the rights issue and placement are part of a regularisation plan to get Pharmaniaga out of PN17 classification, but are likely to have a far-reaching impact if management’s plans pan out.
People still need treatments.. government continue with medical spending!. current price consider reasonable.. between 36 - 38 cents. In my opinion, medical sector will become safe heaven during this turmoil event
this company falls under strategic and security for the nation, asclong as no corrupt or mismanagmnt.. gahmen will always give support. Previous disaster due to previous govt request to stockile vaccine ..in the end, they dont buy. Ltat n bousted..may be replaced by khazanah or pnb, kwsp.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
RInvest
49 posts
Posted by RInvest > 2024-07-05 17:41 | Report Abuse
Some action - news?